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The multiperiod cross-over design is a staple tool for researchers 
in the clinical sciences, primarily for the study of drug treatment 
effects. It is a powerful design which allows direct comparison of 
within- and between-group effects linked to specific treatments 
and their clinical control or sham conditions. Yet, within the clini-
cal cognitive neurosciences, cross-over designs are not routinely 
used. The difficulty presented by cross-over designs in neurocog-
nitive applications is that joining of data from the multiple arms 
of the design has specific statistical requirements that depend on 
washout effects between study periods. This works well for treat-
ments where washout is a typical and expected event, for example 
with pharmaceutical interventions (Senn, 2000). However, for cog-
nitive interventions in neurorehabilitation, treatment objectives 
are often to instate a permanent change to the system which obvi-
ates the notion of washout. Thus, the very success of a cognitive 
treatment brings with it a lack of washout between study periods 
and, thus, the potential for carry-over effects. This is perhaps the 
strongest argument against the use of cross-over designs, and 
perhaps explains why it has not been the design of choice for the 
field of neurocognitive rehabilitation research. As a result, the field 
has not routinely applied a study design that is, for many other 
reasons, well adapted to study functional change in  relation to 
IntroductIon
In the field of speech and language rehabilitation research, there has 
been debate regarding the most appropriate design for evaluating the 
outcomes of treatment. In general terms, the debate has addressed 
the relative advantages and disadvantages of randomized controlled 
trials in comparison to single case or case series designs. A number 
of randomized controlled trials for treatment of developmental and 
acquired speech and language impairments have been conducted 
(e.g., Lincoln et al., 1984; Glogowska et al., 2000), but the methods 
of such trials are often subject to criticism. One key issue is the dif-
ficulty in blinding participants in studies of behavioral interventions 
to the arm of the trial to which they have been randomized. A second 
major issue is that participants often did not receive a single stand-
ard protocol treatment, but rather individuals were administered 
interventions that were appropriate to their particular profile of 
cognitive–behavioral strengths and weaknesses. In the face of such 
problems, Howard (1986) advocated the use of single case research 
designs in order to establish the outcomes of interventions. To some 
degree, the limited generalization from a single case to the larger 
population was addressed through the use of case series designs 
where a number of participants were administered an intervention 
via a standard protocol (e.g., Robertson et al., 1995).
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cognitive  interventions and therapies. For instance, cross-over 
designs are ideal for chronic or incurable medical conditions 
since the power of the repeated measures element of the design 
can be harnessed whereby individuals serve as their own controls 
through the introduction of treatment and sham interventions. 
These are particularly salient benefits for clinical research into 
disorders and disease states that are characterized by population 
heterogeneity, a hallmark of neurocognitive conditions following 
stroke or brain injury.
Applications are seen in clinical research areas related to 
behavioral and cognitive neurorehabilitation, such as neuropsy-
chiatry (Borras et al., 2009), stroke recovery (Mount et al., 2007; 
Ploughman et al., 2008), and cochlear implantation (Petersen 
et al., 2009). Cross-over studies have primarily been employed in 
the field of cognitive rehabilitation for the purpose of allowing 
participants to serve as their own controls. Mount et al. (2007) 
demonstrated this principle in a study designed to contrast error-
less versus trial and error based training of every day motor tasks 
in recovering stroke patients. Cross-over design has also been 
employed to progressively include large numbers of participants 
by offsetting the start point of the study for part of the sample 
(Borras et al., 2009). In the treatment of acquired communication 
disorders, use of cross-over designs is rather limited, particularly 
for group studies. However, there are some published works that 
showcase the potential for wider application of this design; these 
are reviewed below.
Cross-over designs have been used successfully in case series 
studies to track patient-specific responses to therapeutic interven-
tion sequences by contrasting the impact of multiple treatments 
within each patient. For example, Fillingham et al. (2005) conducted 
a series of case studies where cross-over design was used to evaluate 
two therapies for treatment of word finding deficits in seven adults 
with acquired anomia. More recently, Raymer et al. (2010) applied 
a cross-over design to explore the efficacy of errorless versus error-
ful training interventions for spelling in a series of four cases of 
acquired agraphia. Cross-over design was also used to examine the 
combined impact of the pharmacological agent dexamphetamine 
with behaviorally based anomia therapy in two patients with apha-
sia (Whiting et al., 2007). In a larger scale application, Carlomagno 
et al. (2001) applied a multiperiod cross-over design to investigate 
the impact of lexical versus non-lexical therapy on writing abilities 
in patients with aphasia. The key difference in the two study phases 
was the timing of the lexical versus non-lexical therapy period in 
relation to a third non-writing based therapy (Table 1). The authors 
measured for change after each writing-based therapy in relation 
to performance at the most recent checkpoint and for stability in 
relation to the non-writing based therapy. Further analysis, using 
ANOVA, was conducted for data collapsed across phases in order 
to examine the effects of the two types of writing therapy on three 
measures of writing ability. Results were then reported as a func-
tion of main effects for therapy, task and their interactions, making 
this study a good example of the potential that cross-over designs 
have to document the impact of multiple interventions over time. 
Together, the studies reviewed above highlight the values of (1) hav-
ing each case serve as his/her own control; and (2) using multiple 
checkpoints to measure progress along a trajectory of cumulative 
therapeutic change.
A major challenge for researchers in cognitive rehabilitation is 
that the treatments and therapies cannot typically be disguised. 
This precludes cognitive rehabilitation evaluations from some 
of the more stringent aspects of clinical trial design such as the 
double-blind experiment available to other clinical scientists (e.g., 
drug trials). In the field of acquired communication disorders, for 
example, a patient is often acutely aware of their disability and will 
also understand whether or not an intervention involves speech 
and language related content. For this reason, the notion of a sham 
condition compared to a speech–language intervention cannot be 
blinded to the patient-participant in the study. It is also the case 
that distinctions between treatment and control conditions cannot 
be hidden from researchers at the front line of treatment delivery 
and data collection. Indeed, the only stages of the data processing 
pipeline which can be successfully blinded in terms of the alloca-
tion of participants to experimental conditions are data scoring 
and some preliminary aspects of data analysis. The consequences 
of these limitations for researchers are multifold and must be care-
fully considered in the design of treatment studies.
The premise of this article is that the multi-period cross-over 
design can be used to monitor and better understand a range of 
problems in non-blinded neurocognitive treatment studies. Just 
as cross-over designs have proved useful in the implementation of 
case series studies to evaluate communication based therapies, they 
can serve as useful frameworks for larger scale group studies. The 
logical development of these arguments will be made with a pilot 
dataset that was used in the initial stages of our research group’s 
program to investigate the efficacy of computer based treatment 
for acquired communication disorders. Specifically, the methods 
and results sections below will consider treatment effects, “sham” 
or placebo effects, carry-over and other “nuisance” variables in 
the context of conducting an open (i.e., non-blinded) two-period 
cross-over design in the experimental evaluation of cognitive neu-
rorehabilitation for acquired apraxia of speech.
It is not the aim of this paper to argue for the superiority of 
cross-over designs in all cases, or claim that they are always the 
better choice over parallel designs. Rather, the purpose of the cur-
rent paper is to describe how data from therapy experiments can be 
used, with some key considerations in terms of baselines and some 
essential transformations of the dependent measures of interest, to 
allow researchers to harness the power of cross-over designs beyond 
the level of individual case series comparison. It also describes how 
a “lack of washout effects” can actually be exploited in a two-period 
cross-over study to make important and systematic observations 
about functional gains in relation to therapy and its delivery in 
relation to control or sham procedures. Overall, the objective is to 
systematically work through, by way of practical example, both the 
potential benefits and limitations of cross-over designs in the appli-
cation of cognitive neurorehabilitation of acquired  communication 
disorders.
Methods
MethodologIcal consIderatIons
This section provides a detailed methodological rationale for the 
development of novel solutions to measure changes in speech 
production from a study of computerized treatment for acquired 
communication disorders. Factors such as the choice of behavioral 
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benefits of repeated measures analysis. Second, one can evaluate the 
presence of carry-over effects. Carry-over effects have traditionally 
been viewed as the unwanted result of an incomplete washout phase 
between the administration of a pharmacological intervention in 
period 1 and the administration of a placebo in period 2. In severe 
cases, carry-over effects can prevent the joining of the study phases 
and, as a result, restrict analysis to between group comparisons of the 
first period results (Senn, 2000). However, in the current study we 
demonstrate that there is much to be learned about the psychology 
of cognitive neurorehabilitation in relation to changes in the placebo/
sham phase and how the order of delivery, in terms of treatment or 
sham first, can inform the actual rehabilitation process. [See Section 
“Methodological Development” for details of carry-over effect meas-
urement using lambda (λ)]. Finally, the multiple dependent measures 
that are commonly used in cognitive rehabilitation research can be 
probes that are robust to the potential bias of the open cross-over 
design and formulation of raw measures into dependent variables 
sensitive to neurocognitive plasticity will be covered. The inherent 
challenges of defining indices of change, and statistically analyzing 
data for evidence of successful rehabilitation, will be considered 
in light of: (a) the ever-shifting baselines that emerge through the 
course of successive treatment and control procedures; (b) the 
issue of whether or not to combine data from multiple phases of 
a multi-period cross-over design; and (c) individual differences 
in patient severity represented in acquired communicative and 
 cognitive impairments.
There are several aspects of cross-over designs that lend themselves 
to in-depth examination of neurocognitive change. First, one is able 
to follow participants’ progression through two or more interven-
tions using within-subjects comparisons that provide the statistical 
Table 1 | Examples of cross-over study design in the cognitive neurorehabilitation literature. Time points of behavioral or cognitive measurement are 
schematically represented as T1–Tk.
Study Phase T1 T2 T3 T4 T5
Borras et al. 
(2009)
1 Post self esteem 
intervention
Post 12 week rest period
2 Post 12 week wait period Post self-esteem 
intervention
Post 12 week rest 
period
Carlomagno 
et al. (2001)
1 Post traditional therapy Post writing therapy 
(lexical)
Post non-writing 
therapy
Post writing therapy 
(non-lexical)
One month 
follow-up
2 Post traditional therapy Post writing therapy 
(non-lexical)
Post non-writing 
therapy
Post writing therapy 
(lexical)
One month 
follow-up
Fillingham et al. 
(2005)
1 Post naming therapy with 
counterbalanced treatment 
order: Errorful→errorless 
sequence in session 1 of 10
Five week follow-up
2 Post naming therapy with 
counterbalanced treatment 
order: errorless→errorful 
sequence in session 1 of 10
Five week follow-up
Mount et al. 
(2007)
1 Post errorless learning on 
wheelchair task
Post trial and error learning 
on sock donning task
2 Post trial and error learning 
on wheelchair task
Post errorless learning on 
sock donning task
Ploughman et al. 
(2008)
1 Post exercise therapy on 
cognition; Post control task 
on motor ability
Post control task on 
cognition; Post exercise 
therapy on motor ability
2 Post control task on 
cognition; Post exercise 
therapy on motor ability
Post exercise therapy on 
cognition; Post control task 
on motor ability
Raymer et al. 
(2010)
1 During errorful spelling 
therapy
Post errorful spelling 
therapy
During errorless 
spelling therapy
Post errorless 
spelling therapy
One month 
follow-up
2 During errorless spelling 
therapy
Post errorless spelling 
therapy
During errorful 
spelling therapy
Post errorful spelling 
therapy
One month 
follow-up
Whiting et al. 
(2007)
1 During naming therapy with 
dexamphetamine
Post naming therapy with 
dexamphetamine
During naming 
therapy with placebo
Post naming therapy 
with placebo
2 During naming therapy with 
placebo
Post naming therapy with 
placebo
During naming 
therapy with 
dexamphetamine
Post naming therapy 
with 
dexamphetamine
Studies in the area of communication based therapies are highlighted in bold.
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of generative-computational mechanisms in speech control (Varley 
and Whiteside, 2001). Participants received multimodality sensory 
stimulation (auditory, visual orthographic, visual object, somato-
sensory) of whole words prior to attempts at speech production. The 
aim was to activate a broad network of sensory-perceptual zones, 
and mirror neuron mechanisms that integrate input systems with 
action control (Wilson et al., 2004). In order to facilitate the reac-
quisition of cohesive motor patterns, errorless learning and error 
reduction strategies were employed. Before output was required, 
performance was primed by the multimodality stimulation, and 
participants were required to imagine production before overt pro-
duction (Page et al., 2005). Furthermore, the intervention aimed 
to achieve a high dosage of stimulation and massed practice in 
order to facilitate reorganization (Pulvermüller and Berthier, 2008). 
This was achieved by designing software programs that allowed 
the participant to self-administer intervention. Thus, treatment 
could be administered at times and locations convenient to the user, 
and did not require the presence of a clinician. The speech pro-
gram involved stimulation of 30 treated words. In the assessment 
phases, the ability to produce these words was evaluated in terms 
of word accuracy and word duration. Word accuracy represents 
a functional measure which links to the listener’s likely ability to 
understand a word. Word duration was an acoustic measure that 
reflected the cohesiveness and fluency of on-target words (Kent 
and Rosenbek, 1983).
Two types of controls were included within the study. One was 
a set of dependent measures designed to control for possible treat-
ment effects on untreated word items. The other was the inclusion 
of a sham intervention to control for behavioral changes due to the 
introduction of any novel computer task to a patient with com-
munication impairment (i.e., to control for placebo effects). These 
two distinct control mechanisms are described in detail below.
Although not limited to use in cross-over designs, a useful 
element that may be incorporated into treatment studies is a set 
of multiple dependent measures that allow one to evaluate: (a) 
dissociations in relation to communication therapies and sham 
interventions; and (b) potential generalizations between behaviors 
which were specifically targeted to those which were not targeted by 
a given therapy. Therefore, in addition to evaluating performance 
on the treated word set, the production of 30 items from each of 
two untreated word sets was also assessed. In order to explore gen-
eralization of behavioral change, participants produced untreated 
phonetically- and frequency-matched words (e.g., treated word 
“sick”; matched word “sit”), and frequency-matched but phoneti-
cally distinct forms (e.g., treated word “sick”; control word “catch”) 
(Leech et al., 2001). For the purposes of this article, only data from 
treated items will be considered.
With regard to the sham program, this involved no stimulation 
of speech production. The program interfaces mimicked those of 
the speech program, however it contained activities such as short-
term visual memory tasks (recognizing patterns) and timed jig-
saw completion. There was some attempt to blind participants as 
to the sham nature of the program in order to motivate them to 
practice with the sham program with some frequency in order 
that the “dose” levels of the two programs would be equivalent. 
Participants were informed that the program would assist them in 
using a laptop computer and would develop abilities in  attention, 
strategically analyzed in relation to both experimental therapies and 
sham/control interventions (Carlomagno et al., 2001; Fillingham 
et al., 2005; Raymer et al., 2010). Provided a sensitive means of measur-
ing ongoing change can be employed, cross-over designs can be used 
to examine the differential impact of treatment and sham effects, or 
multiple treatment effects, in the context of participant expectations 
and psychological awareness of their own cognitive progress.
PIlot data
The exemplar for this article involves data from a pilot study of 
computerized treatment for apraxia of speech. A subset of data for 
these six cases will be presented in the current article and the entire 
study described in more detail in another paper (Varley et al., in 
preparation). This work provided the basis for a larger scale clini-
cal trial which is currently underway. The pilot sample were six 
participants (one male, five females), adults with acquired apraxia 
of speech, aged 53–83 years (mean = 66 years). All were chronic 
cases with apraxic symptoms ranging from mild to severe (one 
mild, three moderate, two severe) and accompanying symptoms of 
aphasia. The study protocol was approved by The North Sheffield 
NHS Research Ethics Committee (NS200331635) and all partici-
pants provided informed consent prior to taking part.
The study followed a two-period, two-phase cross-over design 
with multiple baselines. The periods consisted of (1) an active 
treatment phase that involved self-administered interaction with 
speech-based computer software, and (2) a sham phase that involved 
self-administered interaction with visuospatial computer software. 
The phases consisted of a “sham first speech second” condition 
and a “speech first sham second” condition. Participants were ran-
domly allocated to the conditions such that three participants were 
studied for each phase. Participants 1–3, allocated to the Speech 
First condition, were three females (severe AOS age 53, mild AOS 
age 59, moderate AOS age 69). Participants 4–6, allocated to the 
Sham First condition, were one male (severe AOS, age 59) and two 
females (ages 70 and 83 years, moderate AOS). Multiple dependent 
measures consisted of target and control behaviors designed to 
respond differentially to the speech based treatment. The design 
structure is presented in Table 2.
The speech program was designed to be consistent with 
principles that maximize sensory-motor components in speech 
processing, and minimize abstract tiers of representation and use 
Table 2 | Two period, two phase cross-over study design for the apraxia 
of speech treatment study. Time points of behavioral measurement are 
represented as B0–B3 for baselines and R1–R4 for reassessment measures 
after interventions. Speech and sham interventions were 6 weeks each in 
duration; the rest phase was 4 weeks in duration; follow-up was conducted 
8 weeks after completion of the second intervention period.
Phase Period 1 Period 2
 B0–B3 R1 R2 R3 R4
1 Sham first Repeated Post Post Post Follow-up 
 baselines sham rest speech
2 Speech first Repeated Post Post Post Follow-up 
 baselines speech rest sham
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comparisons of phonetically similar forms. For each lexical item, 
the duration was measured from its acoustic onset to its acoustic 
offset using spectrographic analysis. Two raters performed the 
speech analysis. Rater 1 was not blind to case, or phase at which the 
speech sample was recorded. Rater 2 analyzed 10% of all samples 
and was blind to case, point of data collection (e.g., baseline, pre-, 
post-speech/sham intervention) and the measurements made by 
Rater 1. Inter-rater correlations revealed high levels of agreement 
(accuracy Spearman’s r = 0.892, p < 0.001; word duration Pearson’s 
r = 0.956, <0.001).
Figures 1 and 2 respectively, show changes in mean accuracy 
and duration for words produced over the course of the study by 
the three participants in phase 1 (Sham First) and the three par-
ticipants in phase 2 (Speech First). In the case of accuracy scores, 
increasing values indicate that speech intelligibility had improved 
and listeners were more likely to accurately understand the word. 
With regard to the durational measure, reduced duration suggests 
greater cohesiveness and fluency in articulatory movement. In 
Figure 1, all data were available for the accuracy measures. This 
is because the ordinal scale allows a score (i.e., zero) even in cases 
where the participant produces no speech response. In contrast, 
for the duration data, if there is no utterance or a response that is 
unrelated or distant from the target, it is not feasible to make an 
acoustic measurement of duration. Hence, there are missing data 
in the duration data sets especially for more severe patients. For 
this reason, the duration data are plotted twice. Figure 2 displays 
means derived for all available data points. Figure 3 shows the same 
data set as presented in Figure 2: but (a) reduced by the cases where 
computations of paired time points involved one missing value; and 
as a result (b) only showing the study time points used in the direct 
evaluation of treatment and sham effects. This issue is discussed 
in more detail below in relation to the computation of delta scores 
(see Results) and specific effects of missing data on the repeated 
measures components of cross-over designs (see Discussion).
perception, and memory. However, participants with speech 
disorders would be aware that the sham program did not target 
communicative abilities.
Participants were instructed to use the programs for a period 
of 30–40 min at least once per day. Both programs recorded the 
interactions the participant had with the software, and the degree of 
compliance with the instruction could subsequently be determined. 
In research with larger samples of patients, the program usage data 
can be used to explore the relationship between treatment dose and 
outcome. Self-administered therapy has advantages, such as therapy 
dose is no longer dependent upon clinician availability. However, 
the amount of treatment is dependent upon the compliance of the 
participant with the dose recommendation. As a result, intervention 
research using this model of service delivery is conducted under 
“field conditions” rather than laboratory conditions in which dose 
levels can be tightly controlled. In this way, there is some blurring 
of the boundary between treatment efficacy research (evaluation of 
the intervention under ideal conditions) and effectiveness research 
(the intervention under realistic, “field” conditions). Reducing the 
translational gap between laboratory and clinic could be seen as 
advantageous, allowing clinicians to make valid inferences concern-
ing the effectiveness of a form of therapy under usual conditions.
The dependent measures of interest for this article consist of 
parallel outcomes for the same sets of spoken words which were 
recorded at each time point for scoring and analysis. Words were 
elicited through a verbal repetition task. Spoken production of 
word items were elicited at each assessment and scored in two 
ways. The first scoring method applied an ordinal scaling of pho-
netic accuracy which ranged from a possible 0–7 rating (0 = lowest 
accuracy to 7 = highest accuracy). The second scoring method 
involved acoustic analysis of the speech waveforms of the lexi-
cal items for precise duration measures (ms). Duration measure-
ments were used to assess the speed and fluency of the lexical items 
which were on target or near to target, in order to allow the paired 
FiguRE 1 | Lexical accuracy scores as a function of speech treatment (SP) and sham treatment (SH) for the two phase conditions defined as Sham First 
and Speech First. Data are for treated items. The full scale of accuracy scores ranges 0–7 (see Pilot Data for additional details).
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periods, but the Sham First demonstrated a more marked shift 
across the three baseline measurements. The effects above were 
probably due in part to the small sample size of this pilot which 
made it vulnerable to these types of phase allocation bias.
A striking commonality in the two sets of measures (Figures 1 
and 2) is the relative impact of speech treatment in comparison to 
sham treatment. For both accuracy and duration, the net change 
from the start to the end of the speech treatment was greater than 
the net change from the start to the end of the sham intervention 
(statistical analysis of effects is covered in the Results section below). 
However, there were also subtle differences in the impact of speech 
and sham interventions as a function of the order in which they 
were delivered; these effects were observed for both accuracy and 
Despite randomized allocation to phase conditions, accuracy 
scores across all three baseline assessments were lower in the Sham 
First group. However, the final baseline (B3) for word duration 
was not markedly different between the groups, but did show an 
approximately 20 ms advantage for participants in the Sham First 
phase. This was due to the factors outlined in the previous para-
graph in relation to loss of utterances suitable for scoring dura-
tion in the more severely impaired patients. A complex pattern of 
similarities and differences in “baseline stability” was also present. 
Although lower in overall accuracy, the Sham First group had com-
parable levels of fluctuation among the three baseline measures to 
the Speech First group. In contrast for duration, the two groups 
showed a comparable range of measures during the experimental 
FiguRE 2 | Lexical duration scores as a function of speech treatment (SP) and sham treatment (SH) for the two phase conditions defined as Sham First 
and Speech First. Data are for treated items (see Pilot Data for additional details).
FiguRE 3 | Lexical duration scores as a function of speech treatment (SP) and sham treatment (SH) for the two phase conditions defined as Sham First 
and Speech First. Due to missing values at some assessment points, only data points used in delta score computations are depicted here (see text for detail).
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important  differences between the two measures. These  phenomena 
emphasize the importance of selecting behavioral measurements 
which tap into different modes of change across the course of treat-
ment for the same set of speech items.
In summary, there was evidence for similar patterns of change 
with accuracy and duration measures. For both, there were greater 
improvements after speech treatment than sham despite the fact 
that there were different patterns of baseline starting points across 
the measures for participants in the Speech First compared to Sham 
First phases. This highlights the need for a technique that allows 
comparable statistical analysis of treatment effects for measures 
such as accuracy (which are non-parametric; more closely linked to 
the whole word experience of participants and “non-blinded data 
collection researchers”) and duration (which are parametric; more 
remote from patient whole word experience, and objectively/pro-
cedurally separable from “non-blinded data collection researcher” 
experience). Such a method would need to account for participant 
differences in multiple key baseline measures across the course 
of the study including the start of the interventions given in both 
period 1 and period 2.
MethodologIcal develoPMent
In the traditional medical cross-over model, the data from the two 
phases of the design are evaluated prior to combining them for sta-
tistical analysis of treatment effects. One important consideration 
is the estimate of any residual carry-over effects from the treatment 
(or possibly sham intervention) that have the capacity to impact 
on the subsequent period of the study. This is done by evaluating 
the magnitude of lambda (λ; Eq. 1), a statistic which compares 
the difference in treatment effect of each study phase to the sham 
effect of the other study phase. Confirmation or rejection of the 
null hypothesis H
0
: λ = 0 determines whether data can be pooled 
across the two phases of the design (Wang and Hung, 1997).
Equation 1: λ = (μ
21
–μ
11
)–(μ
12
–μ
22
) where μ
ik
 represents the 
measurement parameter for phase or condition i (1 = sham first; 
2 = treatment first) and period k (1 = period 1; 2 = period 2).
This statistical approach to two period cross-over models is 
largely based on pharmacological studies where treatment effects 
are physiologically diminished or eradicated during a wash-out 
phase. The post wash-out baseline, in theory, is assumed to be 
equivalent to the initial untreated baseline in the sham-first 
sequence. However, in successful behavioral treatment studies that 
instate more permanent changes to the system, an assumption of 
equivalence between these two baselines is not appropriate. This 
is because performance levels at the start of the sham treatment 
are quite different in the sham-first condition compared to the 
treatment-first sequence. In the sham-first phase, the purpose of 
measurement after period 1 is to show that the sham condition 
does not radically alter the pre-treatment baseline for behaviors 
hypothesized to respond to treatment. This contrasts with the 
conceptual significance of the sham treatment in the speech-first 
phase, where the purpose of measurement after period 2 is to 
document that there has been no additional change subsequent 
to the initial therapeutic improvements following treatment (i.e., 
to measure maintenance effects). These relationships are depicted 
schematically in Table 3, where a key point of comparison is the 
post-rest measurement after period 1 in the treatment first study 
duration. Such details expose important aspects of the cognitive 
neurorehabilitation process that are showcased particularly well in 
the framework provided by the multiple baseline cross-over design. 
Several such patterns of interest are described below.
For accuracy in the Sham First phase, the improvement in rela-
tion to speech treatment was greater than the change in relation to 
the sham intervention. However, improvement in relation to speech 
treatment in the Sham First phase was modest in comparison to 
the speech treatment effect in the Speech First phase. A similar 
trend was observed for the decreases in word duration (a sign of 
improved fluency) after speech treatment which were greater in the 
Speech First phase. There are two explanations for this disparity in 
the impact of treatment for the two phases. One may be that the 
patients in the Sham First phase were less able to make improve-
ments due to the greater severity of word production deficits. A 
second reason could be related to participants’ psychological expe-
rience of the two study periods. Patients are acutely aware of their 
communicative impairments and despite attempts to obscure the 
sham nature of the visuospatial program, will be able to differ-
entiate the likely impact of the two computer programs on their 
impairment. The psychosocial effect of receiving a speech related 
experience early in the study progression may have benefits for the 
participants who were randomly assigned to that phase. Evidence to 
support this claim comes from the data on patients’ interaction with 
the study software. The amount of total time spent actively using the 
speech treatment software differed among patients (range: 18–60 
mean minutes per day) with greater use in the three participants 
in the Speech First condition (Speech First: 43.3 mean minutes per 
day; Sham First: 30.67 mean minutes per day). Total time using 
the sham software was lower than time spent on the speech treat-
ment software for the Speech First group (20.67 mean minutes 
per day), but higher for the Sham First group (41 mean minutes 
per day). Both groups interacted for longer with the program they 
were exposed to in the first compared to the second study period. 
However, a clear differentiation in response occurred in relation 
to program use in the second study period where participants in 
the Sham first phase showed more interaction than participants 
in the Speech first phase. Thus, participants’ motivation may have 
been affected by a combination of factors such as knowledge of 
program content and the order of program delivery. A further level 
of interaction between clinical and psychological response to the 
study protocol is also possible, such that the more severe a patient’s 
symptoms, the more susceptible they are to temporal factors in 
treatment delivery.
For duration, the effect of speech treatment was also greater 
than the changes observed for the sham intervention for partici-
pants in both the Speech First and Sham First study phases. The 
groups had comparable baselines at the start of the first interven-
tion period, but different endpoints with respect to the assessment 
directly following the speech treatment. At baseline 3, the Sham 
First group had an average duration which was ∼20 ms shorter 
than that observed in the Speech First group. However, after speech 
treatment, the difference had widened to ∼50 ms. Difference in the 
direction of sham intervention is also noteworthy and its impact 
on statistical analysis of treatment effects is discussed in the Results 
section. Although both accuracy and duration showed evidence of 
treatment related improvements, microanalysis reveals subtle but 
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interaction term. This modified approach to the cross-over design 
represents a modeling innovation and is detailed in the statistical 
analysis of results from the pilot study data in the next section.
results
This section reports on the computation of delta scores for accu-
racy and then duration of treated words for the six participants 
described above. Computations follow those described by Senn 
(2000), but with the appropriate delta scores used as the index 
of change.
Table 4 (columns 3 and 4) shows data for accuracy of treated 
items as a function of phase (Sham First or Speech First) and period. 
Delta scores for period 1 were computed as the difference in accu-
racy between the final baseline (B3) and the end of the first period 
intervention (R1). Delta scores for period 2 were computed as the 
difference in accuracy between the end of the rest phase (R2) and 
the end of the second period of intervention (R3). Delta scores 
in the negative direction indicate improvement in accuracy. For 
a patient with low accuracy of zero before treatment and higher 
accuracy of 5 after treatment, delta would be −5.
Based on these data, λ = −0.27. This deviation from zero was 
due to the fact, as described above in relation to Figure 1, that 
the average sham effects were similar in both study phases (Phase 
1 = −0.28; Phase 2 = −0.20), but the treatment effect was larger 
in the Speech First phase (Phase 1 = −0.53; Phase 2 = −0.88). In 
summary, the speech treatment effect, over and above the sham 
effect, was present in both periods. However, this effect was greater 
in period 1 (−0.60) than in period 2 (−0.33). The issue of how to 
evaluate the source of this difference and manage it in the course 
of data analysis is not straightforward (Putt and Chinchilli, 1999; 
Wang and Hung, 1997). In the current data set, given the equiva-
lent sham effects, it is possible that the differences in treatment 
effects reflected inherent differences in severity of patients’ clinical 
symptoms between the two study phases (see Figure 1). Also, a 
case by case evaluation of the data shows that for five out of six 
participants, delta scores for the speech treatment were greater 
than delta scores for the sham intervention (scores for participant 
“P6” were equivalent for both). Moreover, the magnitude of λ was 
equivalent to the sham effect. For these reasons, the full cross-over 
design was employed for the next stage of statistical analysis so 
that within-subject analysis could be used. This was deemed to be 
more appropriate than resorting to a between group comparison 
phases. In the pharmacological example, the measurement drops 
back to baseline (from 10 to 1), but in the neurocognitive example, 
change instated in period 1 is maintained (from 10 to 11). This 
leads to a numerical anomaly in computation of change during 
the second period of the cognitive treatment study which seems 
at first glance to represent an increase from 0 at baseline to 14 
after the sham intervention. However, there is a straightforward 
solution for this, as shown in the last two rows of Table 3. Clearly, 
in a cognitive study where neurorehabilitation is taking place, a 
sustained response for repeated measure of the target behaviors 
would be expected, perhaps with some minor fluctuations. One 
must make computations for analysis of any further change, or 
lack thereof, from the end rather than the start of period 1. This 
can be achieved through the use of delta scores.
To accurately model the continuous pattern of change for a given 
set of behaviors over the course of cognitive neurorehabilitation, 
a modified statistical approach is required when estimating both 
carry-over effects and treatment effects. As described above, the 
pilot data for computerized word learning in apraxia of speech 
showed similar rates of increase in performance after the speech 
treatment condition, and a similar lack of change for the sham 
condition, across the two study phases. In this context, one can 
still apply the formula for λ, but must replace the parameter μ 
with ∆, where ∆ signifies the change in performance that occurs 
between the start and end of each key evaluation point (Eq. 2). 
The normalizing effect on the computations is shown in the lower 
two rows of Table 3.
Equation 2: λ = (∆
21
–∆
11
)–(∆
12
–∆
22
) where ∆
ik 
signifies the change 
in performance that occurs during each of the four key stages of 
the study defined by phase i (1 = sham first; 2 = treatment first) 
and period k (1 = period 1; 2 = period 2).
This standardizes the data across the two sham conditions for 
starting performance (i.e., intercept) and allows one to focus instead 
on the presence or absence of change (i.e., slope). In turn, it pro-
vides the appropriate conceptual and numeric basis for computing 
(1) estimates of carry-over effects; (2) adjustments for variations 
in starting baseline (e.g., due to natural variations in symptom 
severity across participants); and (3) treatment effects using the full 
power of the cross-over design. Moreover, in parametric analyses 
that involve general linear models, use of delta scores provides an 
additional means to probe for carry-over effects and assess their 
impact on study results through consideration of the Phase × Period 
Table 3 | Schematic data comparing a pharmacological treatment study (Pharm) to a neurocognitive treatment study (Cog). Both are two period 
cross-over designs with a Sham First (ShTr) and a Treatment First (TrSh) phase.
Study phase Baseline Post period 1 Post rest Post period 2 Computation 21–11 12–22 λ
1 Pharm_ShTr 0 2 1 12 μ 8 9 −1
2 Pharm_TrSh 0 10 1 3    
1 Cog_ShTr 0 3 4 13 μ 7 −1 8
2 Cog_TrSh 0 10 11 14    
1 Cog_ShTr 0 3; ∆ = −3 4 13; ∆ = −9 ∆ −7 −6 −1
2 Cog_TrSh 0 10; ∆ = −10 11 14; ∆ = −3    
Data for the cognitive study are shown twice. In the middle rows, data show computation of effects based on the mean measurements after each period of 
interest. This is contrasted to the same data but with computation of effects based on difference (delta) measures of change between locally relevant “baselines.” 
(Top row: 21 = phase 2, period 1; 11 = phase 1, period 1; 12 = phase 1, period 2; 22 = phase 2, period 2; ∆ = delta; μ = estimate of population mean; λ = lambda).
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the end of the first period intervention (R1). Likewise, delta scores 
for period 2 were computed as the difference in duration between 
the end of the rest phase (R2) and the end of the second period 
intervention (R3). Delta scores in the positive direction indicate 
improvement in spoken word fluency. For a patient with long dura-
tion of 900 ms at baseline and shorter duration of 807 ms after 
treatment, delta would be 93 ms.
Based on these data, λ = −57.42. This deviation from zero was 
due to the fact, as described above in relation to Figure 2, that the 
sham effect in the Speech First phase was of comparable order 
of magnitude to that in the Sham First sequence, but was of the 
opposite sign (i.e., −39.20 signifies an increase in duration rather 
than a decrease). In summary, the speech treatment effect, over and 
above the sham effect, was present in both periods. However, this 
effect was greater in period 2 (118.34) than in period 1 (60.92). 
The matter of how to adjust for the possible differences in the 
two phases of the design can be handled as part of the statistical 
analysis in this case.
Table 5 (columns 5 and 6) displays the duration data in a man-
ner that elucidates the values in relation to the speech and sham 
treatments for both phases. ANOVA was based on unweighted 
mean delta scores from the six participants. Phase (Sham First/
Speech First) was the between group factor and Intervention 
(Sham intervention/Speech treatment) was the repeated measure. 
The Phase × Intervention effect partitions the variance due to any 
differences in the degree to which change in each phase is affected 
by the two interventions; also, the significance of this effect can 
be determined. Results showed a marginally significant effect of 
Intervention (F(1,4) = 6.11, p = 0.069) but no significant effects 
of Phase or Intervention × Phase. Together, the presence of an 
Intervention effect and absence of Intervention × Phase interaction 
indicate that the speech treatment led to decreases in duration for 
both the Speech First and Sham First groups.
dIscussIon
A primary advantage of the multiperiod, multiphase cross-over 
design in cognitive neurorehabilitative research is exemplified in 
the current study of computerized treatment for apraxia of speech. 
Specifically, it takes account of the fact that patients cannot usually 
be blinded to the content of their treatment in relation to their 
disorder. In the current study, for example, it was not possible to 
disguise the speech based content of the treatment or the non-
speech based content of the sham software. Provided no harm-
ful effects of treatment are detected in the first study period, the 
research includes built-in access to the potential benefits of treat-
ment to participants who initially received the sham intervention. 
Moreover, the delivery of both interventions within all patients 
allows researchers to “subtract out” the effects of the treatment 
compared to the sham using each participant as his or her own 
control. The current analyses showed that the design can be used 
not only to document the significance of treatment effects, but can 
be used in a detailed temporal analysis to investigate the treatment 
process as it unfolds over the course of the study. The data from the 
current study suggest that there is a tendency for participants to 
spend more time on the intervention delivered in the first period 
of the study, and possibly also, a subtle interaction between severity 
and temporal sequencing of treatment delivery.
of the two first study periods since it would allow the treatment 
results from participants at all levels of severity to be included in 
the analysis.
Table 4 (columns 5 and 6) displays the same data in a man-
ner that elucidates the values in relation to the speech and sham 
treatments for both phases. Because accuracy ratings were derived 
using an ordinal scale, Wilcoxon signed ranks test was used to com-
pare the delta scores from the speech treatment to those from the 
sham intervention. A significant difference was observed (z = −2.21, 
p < 0.03).
Table 5 (columns 3 and 4) shows data for word duration of 
treated items as a function of phase (Sham First or Speech First) and 
period. As with accuracy, delta scores for period 1 were computed 
as the difference in duration between the final baseline (B3) and 
Table 4 | Accuracy delta scores presented by Phase and for each 
participant (P1–P6).
Phase Participant Period 1 Period 2 Speech Sham
Sham first P4 0.00 −0.37 −0.37 0.00
 P5 0.03 −0.33 −0.33 0.03
 P6 −0.87 −0.90 −0.90 −0.87
 Mean −0.28 −0.53 −0.53 −0.28
Speech first P1 −1.23 −0.33 −1.23 −0.33
 P2 −0.30 −0.07 −0.30 −0.07
 P3 −1.10 −0.20 −1.10 −0.20
 Mean −0.88 −0.20 −0.88 −0.20
Data in columns 3 and 4 are presented by study period. The same data are 
presented in columns 5 and 6 as a function of Speech versus Sham treatment. 
Data are for treated items.
Table 5 | Duration delta scores presented by Phase and for each 
participant (P1–P6).
Phase Participant Period 1 Period 2 Speech Sham
Sham first P4 140.14 78.67 78.67 140.14
 P5 −14.38 68.75 68.75 −14.38
 P6 45.00 90.00 90.00 45.00
 Unweighted 56.92 79.14 79.14 56.92 
 mean
 Weighted 34.08 75.32 75.32 34.08 
 mean
Speech first P1 96.68 −28.54 96.68 −28.54
 P2 40.08 −35.96 40.08 −35.96
 P3 216.76 −53.12 216.76 −53.12
 Unweighted 117.84 −39.20 117.84 −39.20 
 mean
 Weighted 106.47 −39.30 106.47 −39.30 
 mean
Data in columns 3 and 4 are presented by study period. The same data are 
presented in columns 5 and 6 as a function of Speech versus Sham treatment. 
Data are for treated items. Due to different patterns of missing data in terms of 
participants and periods, both weighted (as shown in Figure 3) and unweighted 
(as used in statistical analyses) means are shown.
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However, there remain important questions in communication 
therapy research as to the importance of baseline performance as 
a prognostic indicator of therapeutic response. In a larger scale 
study where random allocation should insure that baseline dif-
ferences are evenly distributed between phases, it is possible to 
statistically measure and adjust for potential correlations between 
baseline indicators (both in absolute level and degree of stability) 
and patient responses. An advantage of cross-over designs is that 
potential baseline effects would be assessed and addressed for both 
treatment and sham interventions in all participants.
The use of delta scores will require systematic evaluation in 
larger scale studies. Prior work in cognitive neurorehabilitation has 
noted normal distribution of delta scores (Ploughman et al., 2008). 
However, the statistical properties of delta scores, in relation to word 
accuracy and duration scores, require further evaluation. Larger 
scale studies will allow investigation as to the impact of the particu-
lar features of individual patient groups and treatment response on 
delta computations and lambda estimates. For example, variation in 
patient dosage via their use of computer based interventions (both 
treatment and sham programs) may impact speech performance. If 
so, the statistical properties of residual delta scores from which dose 
effects have been removed will also need to be studied. Additional 
work is also necessary to determine whether it is more appropriate 
to use weighted or unweighted means in relation to missing data in 
analyses based on composite delta scores. Analysis of a larger scale 
version of the pilot study in this paper, involving 50 participants 
with apraxia of speech, is currently underway and will be used to 
address the issues outlined above.
The current study examined the impact of a computerized 
treatment for AOS, an acquired disorder of communication for 
which comparable computerized therapies are not widely available. 
For this reason, and for the specific purpose of controlling for the 
effects of regular computer based interaction, a single treatment 
compared to a sham intervention was the optimal study design. 
In this context, the cross-over design offered clear benefits which 
are discussed above. However, it may be the case for other types 
of neurocognitive treatment that innovations in the field must be 
compared with previously established therapies. Indeed, this may 
be the case for the currently investigated computer based therapy at 
a point when therapies are developed that give rise to the need for 
multiple-intervention comparisons. Cross-over designs have been 
successfully applied in case series of patients with acquired com-
munication disorders involving multiple treatments or the same 
behavioral treatment delivered under different pharmacological test 
conditions (Fillingham et al., 2005; Whiting et al., 2007; Raymer 
et al., 2010). Results of these studies indicate that by designing 
measures of change through carefully controlled, well-matched 
sets of test items, the cross-over design may be adapted for testing 
multiple treatments with larger samples of patients. For exam-
ple, Raymer et al. (2010) compared therapies for acquired spelling 
impairments using 20 words trained with an errorful procedure 
and 20 psycholinguistically matched words trained with an error-
less procedure. Although some patients reached ceiling perform-
ance on one set of treated items in earlier periods of the study, 
comparison to the alternative treatment in later study periods was 
accomplished through the use of different, but matched sets of test 
items. Similar approaches have been used in cross-over designs of 
The use of delta, or “change scores,” in conjunction with cross-over 
designs is infrequently reported in the rehabilitation literature (e.g., 
Ploughman et al., 2008), particularly in relation to the treatment of 
acquired communication disorders. The current paper demonstrated 
that delta scores provide a sensitive means by which to track the ongo-
ing treatment process in relation to the changing baseline and poten-
tially permanent neurocognitive changes over the course of the study. 
By normalizing indices of change in relation to local baselines, one can 
focus on the net change at each critical juncture in the design. These 
values are useful in statistical comparisons of treatment compared 
to sham interventions, and provide data for computing effect sizes 
and power estimates for future experiments. For the current study 
in apraxia of speech, delta scores revealed relatively large effect sizes 
for both first period and full cross-over repeated measures. However, 
for research into measures which yield small to medium effect sizes, 
the full cross-over design affords additional power provided by cor-
relations across the repeated measures (i.e., periods) of the study. 
When effect sizes are large and repeated measures comparisons can 
be fully powered, even with smaller sample sizes, cross-over designs 
offer potential benefits not only in terms of research outcomes, but 
also for the resourcing of clinical research activity.
We have shown that with a few key computational adjustments, 
cross-over designs can be used to full effect. However, the design 
also has potential disadvantages which must be fully considered. 
These include the dependence on repeated measures such that par-
ticipants must make a relatively long term commitment to remain 
in the study. This could present particular challenges for study 
populations who may be prone to withdraw part way through the 
study by virtue of change in their medical or personal circum-
stances. Other effects that need to be considered include the dif-
ferent experiences of participants randomly assigned to the two 
study phases as a function of whether they receive a treatment or 
sham intervention first. The intervention delivered during the first 
period could affect participant perceptions about its importance 
(i.e., the first intervention may be viewed as the more important 
one), and possibly also their motivations about participation (i.e., 
receiving treatment first may stimulate more software usage). Thus, 
in any study design that includes a multiperiod repeated measures 
component, researchers must be alert to the potential for treatment 
order effects (see also Raymer et al., 2010).
Another difficulty is the management of carry-over effects, or 
any form of order effect in the comparisons between study phases. 
Detection of factors that contribute to the non-zero lambda is one 
challenge for researchers. Removal of the effects is considered a 
fairly controversial statistical issue as it may lead to over-corrections 
or distortions to the data (Wang and Hung, 1997; Senn, 2000). 
Thus, one must ensure that studies are designed with sufficiently 
large sample sizes to provide adequate statistical power for the first 
period between group comparison in the event that large carry-over 
effects or a high number of missing values in period 2 of the study 
preclude using repeated measures. Another recommendation is to 
apply multiple dependent measures, and where theoretically pos-
sible, include at least one set of parametric measures that allow for 
the full factorial investigation of period × phase interactions.
Delta scores proved useful in adjusting the data for differences 
in baseline performance in order to evaluate the specific effects of 
speech treatment and sham intervention in the current pilot study. 
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In a traditional cross-over design application such as the pharma-
ceutical context, positive clinical outcomes would be temporary, and 
expected to wash-out prior to subsequent interventions. However, 
as raised in the Introduction, attainment of excellent clinical out-
comes presents cognitive neurorehabilitation research with a par-
ticular challenge given the semi-permanent nature of the desired 
effects. As emphasized in the previous paragraph, this is a key issue 
for studies where clinical progress is made in an early period of a 
study sequence, particularly if ceiling effects are attained. Indeed, 
in the current study, patients in the Speech First condition showed 
near-ceiling effects on accuracy measures after the first period of the 
study. This raises the question of how one interprets lack of change 
in the subsequent study period after patients have used the sham 
computer program. This is an issue of particular interest in studies 
where the same test items (lexical items in the current study) are 
compared after both study periods. On the one hand, the treatment 
shows evidence of positive outcomes, and the effect is maintained 
through the course of the second period when the patients interact 
with the sham intervention. However, a critical analysis of the data 
raises the possibility that the ceiling effect of treatment precluded 
the possibility of further sham-related improvements, thus reducing 
claims of comparable sham effects from the speech-first and sham-
first study phases. For this reason, researchers interested in imple-
mentation of similar designs are urged to consider multiple means 
of measuring behavioral change. In the current study we examined 
production for each spoken item in terms of both scaled accuracy 
and acoustically measured duration. In contrast to the 0–7 ratings 
used for lexical accuracy, duration measures are not subject to the 
constraints of a defined ceiling effect and therefore allowed us to con-
firm the comparability of sham-based changes across study phases 
for word duration. In the context of the research on which the AOS 
therapy was based (Whiteside and Varley, 1998; Varley and Whiteside, 
2001), the study of word duration was of primary theoretical interest. 
Moreover, it serves as a dependent measure robust to the potential 
problems of ceiling effects in multi-period comparisons.
Ultimately, there is a complex set of trade-offs to consider when 
selecting a study design for cognitive rehabilitation research. For 
example, parallel studies typically require more participants than 
cross-over studies in order to attain equivalent statistical power. 
However, cross-over studies typically need more time points to 
include multiple intervention periods for each participant. Both 
sets of limitations present the clinical researcher with dilemmas to 
overcome. Cross-over study designs offer a combination of benefits 
which until now have been associated mainly with patient case 
series experiments. These include the ability to track responses 
to multiple interventions and to document events that correlate 
with periods of behavioral stability and change – all within a given 
patient. In addition, with cross-over designs, the potential for bene-
fits of a particular treatment to be delivered to all study participants 
is “built in” to the experimental process. This may have benefits 
for participant morale and motivation. In contrast, there may be 
elements of resentful demoralization (Pocock, 1983) for partici-
pants in parallel studies where knowledge of receiving a control 
or treatment intervention is difficult to hide, and where pre-study 
documentation will typically mention that allocation is to only 
one of the two groups. Bias in participant motivation poses spe-
cific problems for research into computer based treatments or any 
intervention that relies on independent participant co-operation 
outside the clinic or laboratory. The factors discussed above would 
ideally be tested through small scale pilot work. If early pilot work 
indicated that the logistics of large scale longitudinal research were 
experimentally infeasible or financially prohibitive, then cross-over 
designs would not be the most suitable choice. If however, the par-
ticular subfield of research was theoretically poised to support such 
work and resourcing was available, then the benefits of conducting 
research with fully powered multi-phase multi-period cross-over 
designs would be worth serious consideration.
In conclusion, the multiphase, multiperiod cross-over design is 
ideally suited for cognitive neurorehabilitation research. It provides 
the basis for microanalysis of change sequences for individual par-
ticipants, and participant groups, as a function of experimental and 
control interventions. The elegance of the repeated measure design 
is that it allows within-subject comparisons of multiple cognitive 
interventions. When used in conjunction with treatment-sham 
delivery procedures that are based on valid neurofunctional disso-
ciations and delta score computations, the cross-over design func-
tions in a manner which is conceptually analogous to task-based 
comparison techniques used in functional neuroimaging where 
brain activation is compared across task or stimulus types with 
counterbalanced order of delivery. Thus, well designed behavioral 
studies in cognitive neurorehabilitation research have the potential 
to be adapted as the basis for, and to provide convergent evidence 
with, parallel cognitive neuroactivational experiments. From this, 
a better integrated cognitive neuroscience for the study of treat-
ment and recovery in acquired communication disorders could 
be achieved.
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